# A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

> **NCT00427362** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 127 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT00427362
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2008-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427362, "A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00427362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*